Auris Medical (Switzerland)
Altamira Therapeutics AG is developing and supplying peptide-based nanoparticle technologies for efficient nucleic acid delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different nucleic acid modalities, including siRNA, mRNA, circRNA, as well as DNA, and made available to pharma or biotech companies through out-licensing. We are a holding company with affiliates active in the development and commercialization of technologies and products for imp
Basic Information
- Category: business
- Website: http://www.aurismedical.com/
Documented Facts
- Inception (Wikidata): 2003 (Source 3: Wikidata Q30268734, revision 2474419258)
- Country (Wikidata; date unspecified): Switzerland (Source 3: Wikidata Q30268734, revision 2474419258; Source 4: Wikidata label: Q39, revision 2550802861)
- Official website (Wikidata; date unspecified): http://www.aurismedical.com/ (Source 3: Wikidata Q30268734, revision 2474419258)
Evidence and Sources
- Auris Medical (Switzerland) — Official Site (official)
- Auris Medical (Switzerland) on linkedin (social)
- Wikidata Q30268734, revision 2474419258 (knowledge-base)
- Wikidata label: Q39, revision 2550802861 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Auris Medical (Switzerland).
- Canonical profile: https://brandsource.ai/brands/auris-medical-switzerland
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/auris-medical-switzerland/json-ld
- Citation profile API: https://brandsource.ai/api/brands/auris-medical-switzerland/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Altamira Therapeutics AG is developing and supplying peptide-based nanoparticle technologies for efficient nucleic acid delivery to extrahepatic tissues (xPhore™ platform). The versatile delivery platform is suited for different nucleic acid modalities, including siRNA, mRNA, circRNA, as well as DNA, and made available to pharma or biotech companies through out-licensing. We are a holding company with affiliates active in the development and commercialization of technologies and products for imp
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 3 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.